We are live on ! Find out more
VVOS icon

Vivos Therapeutics
VVOS

28 hedge funds and large institutions have $861K invested in Vivos Therapeutics in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.03% less ownership

Funds ownership: 0.63% → 0.6% (-0.03%)

7% less funds holding

Funds holding: 30 → 28 (-2)

22% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 9

64% less capital invested

Capital invested by funds: $2.39M → $861K (-$1.53M)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

Holders
28
Holders Change
-2
Holders Change %
-6.67%
% of All Funds
0.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
–
Reduced
4
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
+$26.5K
2
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services
Minnesota
+$16.1K
3
HighTower Advisors
HighTower Advisors
Illinois
+$5.63K
4
UBS Group
UBS Group
Switzerland
+$2.79K
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$60

Top Sellers

Rank Fund Capital Flow
1
GGI
Godsey & Gibb Inc
Virginia
-$47.4K
2
Two Sigma Investments
Two Sigma Investments
New York
-$32.3K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$29.9K
4
VF
Virtu Financial
New York
-$26K
5
Renaissance Technologies
Renaissance Technologies
New York
-$17K
Name Holding Trade Value Shares
Change 		Change in
Stake
SWIG
1
Strategic Wealth Investment Group
Kentucky
$619K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$118K -$29.9K -3,963 -14%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$38.8K – – –
HF
4
HRT Financial
New York
$16K +$26.5K +3,508 New
Credit Agricole
5
Credit Agricole
France
$11.4K – – –
Wealth Enhancement Advisory Services
6
Wealth Enhancement Advisory Services
Minnesota
$10.2K +$16.1K +2,133 New
State Street
7
State Street
Massachusetts
$8.77K – – –
AF
8
Apexium Financial
Texas
$7.81K – – –
LPL Financial
9
LPL Financial
California
$6.82K – – –
Northern Trust
10
Northern Trust
Illinois
$5.7K – – –
HighTower Advisors
11
HighTower Advisors
Illinois
$4K +$5.63K +746 New
PCM
12
Perkins Capital Management
Minnesota
$3K -$1.66K -220 -27%
LNC
13
Lincoln National Corp
Pennsylvania
$2.85K – – –
S
14
SignatureFD
Georgia
$2.63K – – –
BTI
15
Blue Trust Inc
Georgia
$2K – – –
UBS Group
16
UBS Group
Switzerland
$1.78K +$2.79K +370 New
CG
17
Cutler Group
California
$1K – – –
KA
18
Kozak & Associates
Colorado
$335 – – –
Morgan Stanley
19
Morgan Stanley
New York
$320 – – –
BlackRock
20
BlackRock
New York
$199 -$393 -52 -56%
GRP
21
Global Retirement Partners
California
$174 – – –
Group One Trading
22
Group One Trading
Illinois
$41 – – –
SPIA
23
Steward Partners Investment Advisory
New York
$38 – – –
Qube Research & Technologies (QRT)
24
Qube Research & Technologies (QRT)
United Kingdom
$38 +$60 +8 New
Wells Fargo
25
Wells Fargo
California
$30 – – –
1
2

VVOS Hedge Fund Activity: Q3 2023 in Review

28 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q3 2023, worth a combined $861K — down 64% from $2.39M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of VVOS and 7 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 0 added.

The largest buyer was HRT Financial, opening a new position worth an estimated $26.5K. The largest seller was Godsey & Gibb Inc, exiting entirely with an estimated $47.4K sold.

  • 28 institutional investors held Vivos Therapeutics (VVOS) as of Q3 2023, down from 30 in Q2 2023.
  • Funds reported $861K of Vivos Therapeutics stock for Q3 2023, down 64% quarter-over-quarter.
  • 7 funds opened new Vivos Therapeutics positions in Q3 2023 and 9 closed out, a net change of -2 holders.
  • The largest Vivos Therapeutics buyer in Q3 2023 was HRT Financial, an estimated $26.5K added.
  • The largest Vivos Therapeutics seller in Q3 2023 was Godsey & Gibb Inc, an estimated $47.4K sold.

Based on aggregated 13F filings for Q3 2023.